Therapeutic activities of anti‐human SIGLEC10 mAb in Multiple Transgenic Mouse AD Models

In two AD mouse models, anti-SIGLEC10 cleared the amyloid plaques or reduced the plasma p-Tau biomarkers. The clinical stage anti-SIGLEC10 antibody, ONC-841, promotes phagocytosis of protein aggregates. ONC-841 protects against AD pathogenic process in the mice by rejuvenating microglia functions. These studies provided the scientific foundation for further clinical development with ONC-841 as potential microglia targeting immunotherapy agent for AD.